OncoMatch/Clinical Trials/NCT04765098
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
Is NCT04765098 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tamoxifen and Etoposide for glioblastoma multiforme.
Treatment: Tamoxifen · Etoposide — The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemoradiotherapy with temozolomide (temozolomide) — first line
progression after previous first line chemoradiotherapy with temozolomide
Cannot have received: radiotherapy
Exception: allowed if not received within the three months before the diagnosis of progression
Not received radiotherapy within the three months before the diagnosis of progression
Lab requirements
Blood counts
anc ≥ 1.5 x 10^9/l; platelets ≥ 100 x 10^9/l
Kidney function
serum creatinine ≤ 1.5 times uln
Liver function
total serum bilirubin ≤ 1.5 times uln; alt < 3 times uln; ast < 3 times uln; alkaline phosphatase < 3 times uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify